Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Heat-killed Mycobacterium tuberculosis prime-boost vaccination induces myeloid-derived suppressor cells with spleen dendritic cell–killing capability
Eliana Ribechini, … , Uwe Ritter, Manfred B. Lutz
Eliana Ribechini, … , Uwe Ritter, Manfred B. Lutz
Published June 4, 2019
Citation Information: JCI Insight. 2019;4(13):e128664. https://doi.org/10.1172/jci.insight.128664.
View: Text | PDF
Research Article Immunology Infectious disease

Heat-killed Mycobacterium tuberculosis prime-boost vaccination induces myeloid-derived suppressor cells with spleen dendritic cell–killing capability

  • Text
  • PDF
Abstract

Tuberculosis patients and mice infected with live Mycobacterium tuberculosis accumulate high numbers of myeloid-derived suppressor cells (MDSCs). Here, we hypothesized that dead M. tuberculosis vaccines also may induce MDSCs that could impair the efficacy of vaccination. We found that repeated injections of M. tuberculosis vaccines (heat-killed M. tuberculosis in incomplete Freund’s adjuvant, such as Montanide) but not single or control vaccines without M. tuberculosis strongly expanded CD11b+ myeloid cells in the spleen, leading to T cell suppression of proliferation and killing ex vivo. Dead M. tuberculosis vaccination induced the generation of CD11b+Ly6ChiCD115+ iNOS/Nos2+ monocytic MDSCs (M-MDSCs) upon application of inflammatory or microbial activation signals. In vivo these M-MDSCs were positioned strategically in the splenic bridging channels and then positioned in the white pulp areas. Notably, within 6–24 hours, in a Nos2-dependent fashion, they produced NO to rapidly kill conventional and plasmacytoid DCs while, surprisingly, sparing T cells in vivo. Thus, we demonstrate that M. tuberculosis vaccine induced M-MDSCs do not directly suppress effector T cells in vivo but, instead, indirectly by killing DCs. Collectively, we demonstrate that M. tuberculosis booster vaccines induce M-MDSCs in the spleen that can be activated to kill DCs. Our data suggest that formation of MDSCs by M. tuberculosis vaccines should be investigated also in clinical trials.

Authors

Eliana Ribechini, Ina Eckert, Andreas Beilhack, Nelita Du Plessis, Gerhard Walzl, Ulrike Schleicher, Uwe Ritter, Manfred B. Lutz

×

Figure 3

Systemic LPS/IFN-γ administration induces MDSC infiltration into the splenic white pulp.

Options: View larger image (or click on image) Download as PowerPoint
Systemic LPS/IFN-γ administration induces MDSC infiltration into the spl...
(A) Spleens from untreated (Ctrl) and CFA- and CFA/CFA-immunized mice were collected after 15 days, and cryosections were stained for iNOS, B220, and CD11c. (B) WT and Nos2–/– mice were CFA/CFA injected and challenged with i.p. LPS/IFN-γ administration for 6 hours. Then spleens were stained for B220, CD11b, Ly6G, and CD3 as indicated. All microscopy data are representative of 3 independent experiments (n = 3 mice). Scale bars: 100 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts